Publications by authors named "Kyungyeon Jung"

Objective: Menopausal hormone therapy (MHT) is the most effective treatment for menopausal symptoms. While guidelines recommend an individualized risk-benefit assessment of MHT, real-world studies on use of MHT are limited.

Method: Nationwide claims data in South Korea (2015-2020) were used to assess the prevalence of hospital visits for menopausal symptoms and use of MHT among women aged 40-59 years.

View Article and Find Full Text PDF

Purpose: Anbalcabtagene autoleucel (anbal-cel) is a second-generation CD19-targeted chimeric antigen receptor-T cell therapy reducing T-cell exhaustion through PD-1 and TIGIT downregulation. We compared efficacy of anbal-cel with tisagenlecleucel (tisa-cel) in relapsed/refractory diffuse large B-cell lymphoma using external control arm study design.

Materials And Methods: We performed a matching-adjusted indirect comparison (MAIC) using individual patient data from CRC01-01 (NCT#04836507) and aggregate data from JULIET trial (NCT#02445248).

View Article and Find Full Text PDF

Objectives: This study investigated the safety of azilsartan and amlodipine combination therapy versus other angiotensin receptor blockers (ARBs) and amlodipine in patients with hypertension.

Methods: We conducted a cohort study utilizing healthcare databases from Korea and Taiwan. Patients aged between 18 years and 75 years who were newly prescribed both an ARB and amlodipine within 6 months of hypertension diagnosis were included.

View Article and Find Full Text PDF

Background/objectives: Influenza poses a significant risk for young children, particularly those under five. Cell culture-derived influenza vaccines offer advantages in reducing adaptive changes and mitigating egg allergy concerns. SKYCellflu quadrivalent has been in use since 2015, and this study aimed to assess its safety and influenza infections in children aged 6-35 months in South Korea.

View Article and Find Full Text PDF

Aims: To evaluate the risk of incident dementia associated with sacubitril/valsartan in patients with heart failure (HF) in South Korea.

Methods And Results: We conducted a retrospective cohort study using the National Health Insurance Database in South Korea. Patients diagnosed with HF and prescribed either sacubitril/valsartan or angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) within 90 days of their first HF diagnosis between October 2017 and December 2020 were included.

View Article and Find Full Text PDF

Aims: There is limited evidence regarding whether obesity modifies the association between the use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and the risk of cardiovascular events. We assessed whether baseline body mass index (BMI) modifies the association between SGLT2i use and the risk of major adverse cardiovascular events (MACE) and heart failure (HF) in patients with type 2 diabetes (T2D).

Materials And Methods: We used the nationwide claims data of Korea (September 2014-December 2022) to construct an active-comparator, new-user cohort of patients with T2D stratified by the Asian BMI categories: normal weight, 18.

View Article and Find Full Text PDF

Background: Evidence comparing the impact of various biologics for psoriasis on the progression to psoriatic arthritis (PsA) is limited. We therefore assessed the risk of PsA associated with interleukin (IL)-23 inhibitor, IL-17 inhibitor, or IL-12/23 inhibitor use compared with tumor necrosis factor (TNF) inhibitor use among patients with psoriasis.

Methods: This population-based cohort study used the nationwide claims database from South Korea (2007-2023).

View Article and Find Full Text PDF
Article Synopsis
  • A study in South Korea analyzed the link between COVID-19 vaccinations and facial palsy (FP) in over 44 million patients aged 18 and above who received vaccines from various brands.
  • Researchers compared the incidence of FP within 28 days following vaccination (risk window) to the incidence during the remainder of a 240-day observation period (control window).
  • They found an increased risk of FP within the first 28 days post-vaccination, especially after the first and second doses, and recommended that clinicians evaluate the risk of FP when considering vaccination and monitor for neurological symptoms afterward.
View Article and Find Full Text PDF

Background: Several neurological manifestations shortly after a receipt of coronavirus infectious disease 2019 (COVID-19) vaccine have been described in the recent case reports. Among those, we sought to evaluate the risk of encephalitis and meningitis after COVID-19 vaccination in the entire South Korean population.

Methods: We conducted self-controlled case series (SCCS) analysis using the COVID-19 immunization record data from the Korea Disease Control Agency between February 2021 and March 2022, linked with the National Health Insurance Database between January 2021 and October 2022.

View Article and Find Full Text PDF